Eupraxia Pharmaceuticals Presents Innovative Research at ACG Annual Meeting
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotech leader, is thrilled to announce its participation in the Annual Scientific Meeting hosted by the American College of Gastroenterology (ACG) in 2024. This annual gathering stands out as a premier event for gastrointestinal professionals, focused on education and advancement in digestive health.
Exciting Posters at the ACG Meeting
At the event, Eupraxia will unveil two cutting-edge research posters that delve into its DiffuSphere™ technology, which aims to improve drug delivery processes for gastrointestinal treatments.
Poster One: EP-104GI for Eosinophilic Esophagitis
The first poster, designated as P2209, titled "Pharmacokinetics and Local Tolerability of EP-104GI, an Extended-Release Formulation of Fluticasone for Treatment of Eosinophilic Esophagitis, after Intra-Esophageal Injection in Mini-Pigs," will be presented on a special session set for October 28, 2024.
This research showcases how EP-104GI, a proprietary product by Eupraxia, demonstrated promising results through its innovative delivery strategy aimed at treating eosinophilic esophagitis (EoE). This non-clinical poster received a prestigious Presidential Award for its noteworthy findings, reflecting high quality and relevance in research.
Poster Two: Ongoing Clinical Studies
The second poster, numbered P3911, focuses on "Efficacy and Pharmacokinetic Results From Ongoing Dose Escalation in RESOLVE, a Phase 1b/2a Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis." Scheduled for presentation on October 29, this poster addresses key data collected from a vital ongoing trial.
Notably, this poster has been identified as an "Abstract of Interest" at the conference, underscoring the significance of the information presented.
About Eupraxia and Its Commitment to Innovation
Eupraxia Pharmaceuticals is distinguished by its dedication to developing innovative therapies targeting high unmet medical needs. Central to its mission is the proprietary DiffuSphere™ technology, which is engineered to enable localized and controlled drug delivery. This technology is instrumental for clinicians looking to enhance treatment outcomes while minimizing adverse reactions that may arise from traditional drug delivery methods.
The company’s key product, EP-104GI, represents a breakthrough approach in treating eosinophilic esophagitis through a localized injection method aimed at delivering active ingredients directly to affected tissues. Furthermore, Eupraxia has also recently achieved success with another product, EP-104IAR, finalized in a robust Phase 2b clinical trial targeting knee osteoarthritis, achieving significant milestones.
Future Outlook and Pipeline Development
Eupraxia's research portfolio is rich and diverse, with additional ongoing studies aiming to extend the benefits of its formulation techniques into broader therapeutic areas, including oncology and infectious disease. The promise of transforming existing drugs through enhanced delivery systems continues to shape Eupraxia’s vision and potential market stance.
As the company progresses through clinical trials, it remains steadfast in its goal to push the boundaries of what is possible in drug delivery and treatment efficacy, aspiring to improve patient experiences significantly.
Frequently Asked Questions
What is the significance of Eupraxia's presentations at the ACG?
Eupraxia's presentations highlight groundbreaking research in drug delivery methods, especially for eosinophilic esophagitis, showcasing their commitment to innovative treatments.
Who are the presenters for the posters?
Dr. Amanda Malone and Dr. Evan Dellon will present the posters detailing the company’s ongoing research at the ACG Annual Meeting.
What technology does Eupraxia Pharmaceuticals use?
Eupraxia utilizes DiffuSphere™, a proprietary technology designed to enable localized and controlled drug release, enhancing treatment efficacy and safety.
Why is the PRESOLVE trial important for Eupraxia?
The RESOLVE trial is crucial as it involves EP-104GI, a promising treatment for eosinophilic esophagitis, and its findings could shape future therapeutic strategies.
Where can I find more information on Eupraxia Pharmaceuticals?
Further details about Eupraxia Pharmaceuticals and its innovative products are available on their official website, which provides insights into ongoing clinical trials and research developments.
